Page last updated: 2024-12-07

dicyclohexyl-18-crown-6

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID85955
CHEMBL ID155379
SCHEMBL ID35551
MeSH IDM0043227

Synonyms (65)

Synonym
BB 0261748
perhydrodibenzo-18-crown-6
nsc252171
dicyclohexyl-18-crown-6 ether
dibenzo[b,4,7,10,13,16]hexaoxacyclooctadecin, eicosahydro-
16069-36-6
dicyclohexo-18-crown-6
dicyclohexyl-18-crown-6
2,8,15,18,21-hexaoxatricyclo[20.4.0.09,14]hexacosane
perhydrodibenzo[18]crown-6
nsc-252171
dicyclohexano-18-crown-6
dibenzo[b,4,7,10,13,16-hexaoxacyclooctadecin, eicosahydro-
dch-18-crown-6
einecs 240-216-4
dicyclohexyl 18-crown-6
dibenzo(b,k)-1,4,7,10,13,16-hexaoxacyclooctadecin, eicosahydro-
ai3-62377
icosahydrodibenzo(b,k)(1,4,7,10,13,16)hexaoxacyclooctadecin
nsc 252171
2,5,8,15,18,21-hexaoxatricyclo(20.4.0.0(sup 9,14))hexacosane
cis-dicyclohexano-18-crown-6
dibenzo(b,k)(1,4,7,10,13,16)hexaoxacyclooctadecin, eicosahydro-
ccris 3612
d2-06
2,5,8,15,18,21-hexaoxatricyclo(20.4.0.09,14)hexacosane
2,3,11,12-dicyclohexano-1,4,7-10,13,16-hexaoxacyclooctadecane
brn 1130529
dibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin, eicosahydro-
CBDIVE_001514
dicyclohexano-18-crown-6, 98%
icosahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecine
STK796822
AKOS000519878
CHEMBL155379
inchi=1/c20h36o6/c1-2-6-18-17(5-1)23-13-9-21-11-15-25-19-7-3-4-8-20(19)26-16-12-22-10-14-24-18/h17-20h,1-16h2
bbgkdyhzqosnmu-uhfffaoysa-
dicyclohexano-18-crown 6-ether
D1668
perhydro-dibenzo-18-crown-6
2,5,8,15,18,21-hexaoxatricyclo[20.4.0.09.14]hexacosane
2,3,11,12-dicyclohexano-1,4,7,10,13,16-hexaoxacyclooctadecane
BBL009691
FT-0624739
AKOS016344456
icosahydrodibenzo[b,k][1,4,7,10,13,16]-hexaoxacyclooctadecine
SCHEMBL35551
dicyclohexyl-18 -crown-6
dicyclohexano-l 8-crown-6
crown ether dicyclohexyl-18-crown-6
dicyclohexano-18-crown-6 ether
2,5,8,15,18,21-hexaoxatricyclo[20.4.0.0(9,14)]hexacosane
mfcd00005099
J-009746
2,5,8,15,18,21-hexaoxatricyclo[20.4.0.0?,(1)?]hexacosane
VS-02149
D78390
2,5,8,15,18,21-hexaoxatricyclo[20.4.0.09,14]hexacosane
DTXSID30884870
A883190
dicyclohexano-18-crown-6,mixture of isomers
CS-W009764
SY010002
2,5,8,15,18,21-hexaoxatricyclo[20.4.0.0,9,14]hexacosane
EN300-18470780
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1614582Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 0.2 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID280247Antiproliferative activity against MiaPaCa2 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID50775In vitro lethal dose of compound against Eimeria tenella in chicken kidney cell cultures1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Anticoccidial activity of crown polyethers.
AID1614581Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 2 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614591Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as increase in BC50 for ANS binding to TTR at 100 mM in presence of 150 mM Na+ by fluorescence-based assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614583Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 0.6 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614594Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as increase in BC50 for ANS binding to TTR at 10 mM in presence of 150 mM K+ by fluorescence-based assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID280248Antiproliferative activity against SW620 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID280246Antiproliferative activity against HeLa cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1614584Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 10 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID611986Antibacterial activity against Bacillus subtilis after 70 mins2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns.
AID1614592Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as increase in BC50 for ANS binding to TTR at 10 mM in presence of 150 mM Na+ by fluorescence-based assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID280249Antiproliferative activity against MCF7 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID611984Antibacterial activity against Escherichia coli assessed as growth inhibition at 10'-4 M after 105 mins2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns.
AID280245Antiproliferative activity against H460 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (28.57)18.7374
1990's1 (4.76)18.2507
2000's3 (14.29)29.6817
2010's9 (42.86)24.3611
2020's2 (9.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.52 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]